

18th John Vane Memorial Symposium on Prostacyclin Science & Pulmonary Vascular Disease

Faculty Chair

Chris Thiemermann, Queen Mary University of London, UK

Session Chairs

Michele D'Alto, Mondali Hospital, Naples, Italy
Ardeschir Ghofrani, University of Giessen, Giessen, Germany
Marc Humbert, University of Paris-Saclay, Paris France
Vallerie McLaughlin, University of Michigan, Ann Arbor, USA
Vinicio de Jesus Perez, University of Stanford, Stanford, USA
Franck Rahaghi, The Cleveland Clinic, Weston, USA
Chris Thiemermann, Queen Mary University of London, UK
Mark Toshner, Addenbrookes Hospital, Cambridge, UK
Dario Vizza, La Sapienza University, Rome, Italy
Jim White, University of Rochester, Rochester, USA
Brendan Whittle, Queen Mary University of London, UK

17th and 18th March 2023

The Royal Society
6-9 Carlton House Terrace, London, SW1Y 5AG, UK

CPD credits - TBC

Friday, 17th March 2023

08.30-09.20 Registration, tea and coffee

09.20 Welcome
Chris Thiemermann, Queen Mary University of London, UK

Session I

Chairs: *Chris Thiemermann, Queen Mary University of London, UK*
Brendan Whittle, Queen Mary University of London, UK

09.30 Molecular Subsets of Pulmonary Hypertension
Allan Lawrie, Imperial College London, London, UK

10.00 Multimodality Imaging and AI in the Diagnosis and Assessment of Pulmonary Hypertension
David Kiely, Sheffield Teaching Hospitals NHS Trust, Sheffield, UK

10.30 Refreshments

Session II

Chairs: *Mark Toshner, Addenbrookes Hospital, Cambridge, UK*
Dario Vizza, La Sapienza University, Rome, Italy

11.00 Pulmonary Hypertension in Patients with COPD
Dario Vizza, La Sapienza University, Rome, Italy

11.30 Pulmonary Hypertension in Congenital Heart Disease?
George Giannakoulas, Aristotle University of Thessaloniki, Thessaloniki, Greece

12.00 Autoimmunity and Idiopathic Pulmonary Hypertension
Mark Toshner Addenbrookes Hospital, Cambridge, UK

12.30 Lunch

Session III

Chairs: *Michele D'Alto, Mondali Hospital, Naples, Italy*
Franck Rahaghi, The Cleveland Clinic, Weston, USA

14.00 What is a Disease-Modifying Therapy in PH?
Franck Rahaghi, The Cleveland Clinic, Weston, USA

14.30 Combination therapies in PAH: Are Prostacyclins dispensable?
Michele D'Alto, Mondali Hospital, Naples, Italy

15.00 Antifibrotic Effects of Inhaled Treprostinil: An Emerging Option for Interstitial Disease
Stylianos E Orfanos, Evangelismos General Hospital, Athens, Greece

15.30 Refreshments

Session IV

Chairs: *Vallerie McLaughlin, University of Michigan, Ann Arbor, USA*
Sandeep Sahay, Houston Methodist Hospital, Houston, USA

16.00 Risk Management and Medical Therapy for PH
Vallerie McLaughlin, University of Michigan Health, Ann Arbor, USA

16.30 Assessed versus Actual Risk of PH?
Sandeep Sahay, Houston Methodist Hospital, Houston, USA

17.00-18.30 Meeting Adjournment and Evening Reception at the Royal Society

Saturday, 18th March 2023

08.30 Tea and coffee

Session V

Chairs: *Ardeschir Ghofrani, University of Giessen, Giessen, Germany*
Marc Humbert, University of Paris-Saclay, Paris, France

09.30 2022 ESC/ERS Guidelines for the Diagnosis and Treatment of PH
Marc Humbert, University of Paris-Saclay, Paris, France

10.00 New Study Designs for Clinical Trials in PH: Is it prime time to consider different endpoints depending on the mechanism of action?
Ardeschir Ghofrani, University of Giessen, Giessen, Germany

10.30 What Liquid Biopsies can tell us about PAH: Diagnosis and Risk
Martin Wilkins, Imperial College, London, UK

11.00 Refreshments

Session VI

Chairs: *Vinicio de Jesus Perez, University of Stanford, Stanford, USA*
Jim White, University of Rochester, Rochester, USA

11.30 Freedom EV: Risk Scores, Events and Mortality
Jim White, University of Rochester, Rochester, USA

12.00 Patient Perspective in Treatment Planning in PH
John Ryan, University of Utah, Salt Lake City, USA

12.30 Global Perspective of Patient Care Access
Vinicio de Jesus Perez, University of Stanford, Stanford, USA

13.00 Lunch

14.00 Close of meeting